Scynexis (SCYX) Cash from Investing Activities (2013 - 2026)
Scynexis' (SCYX) quarterly Cash from Investing Activities came in at -$525000.0 in Q1 2026, down 104.22% YoY from $12.4 million in Q1 2025, and up 95.56% on a QoQ basis from -$11.8 million in Q4 2025.
Scynexis (SCYX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Cash from Investing Activities data on file, last reported at -$525000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 104.22% year-over-year to -$525000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 13.66% YoY) and the FY2025 annual result came in at $24.3 million, up 295.22% from the prior year.
- Cash from Investing Activities grew to -$525000.0 in Q1 2026, from -$11.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $12.4 million in Q1 2025 to a low of -$27.4 million in Q3 2022.
- A 5-year average of -$2.3 million and a median of -$267000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 8000.59% — and 2025, when it surged 721.65%.
- Tracing SCYX's Cash from Investing Activities over 5 years: stood at -$27.4 million in 2022, then surged by 92.14% to -$2.2 million in 2023, then dropped by 21.61% to -$2.6 million in 2024, then tumbled by 351.82% to -$11.8 million in 2025, then jumped by 95.56% to -$525000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$525000.0 (Q1 2026), -$11.8 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | -24.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.76 Mn |
| Jun 30, 2026 | -24.76 Mn |
| Mar 31, 2026 | -525,000.00 |
| Mar 31, 2026 | -525,000.00 |
| Dec 31, 2025 | -11.82 Mn |
| Dec 31, 2025 | -11.82 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Mar 31, 2024 | 5.45 Mn |